The development of protein formulations for administration of monoclonal antibodies (mAbs) is an important and growing field in pharmaceutical biotechnology [1]. The low solubilities achieved in state of the art formulations commonly only allows their administration via intravenous injection [1]. An increase in protein concentration, which enables the subcutaneous administration, requires the addition of suitable excipients / excipient mixtures to stabilize the protein in solution and increase solubility. A method for their identification, furthermore delivering a mechanistic understanding, will be identified within this work.

Further information